Tabellvi for moderate to severe Crohn's disease in adults
Part of Digestive system clinical trials.
This trial tests Tabellvi (adalimumab) for adults with moderate to severe Crohn's disease who haven't responded well to steroids or other treatments. It aims to see if this medication can help control symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have moderate to severe Crohn's disease that hasn't improved enough with steroids or other therapies.
- Your doctor has decided that Tabellvi is a good option for you based on a careful review of risks and benefits.
- If you can become pregnant, you must use an effective birth control method during the study.
- You cannot have active infections, certain past infections (like tuberculosis, HIV, hepatitis B or C), or serious heart problems.
- You cannot have had surgery for Crohn's in the last 6 months or plan to have it soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.